Global Actinic Keratosis Treatment Market to Reach US$ 9.7 Billion by 2032, Propelled by Rising Prevalence of Actinic Keratosis

November 18, 2022 | Healthcare

According to the latest report by IMARC Group, titled “Actinic Keratosis Treatment Market Report by Type (Prescription, OTC), Drug Type (Fluorouracil, Imiquimod, Diclofenac, and Others), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Stores), and Region 2024-2032," the global actinic keratosis treatment market size reached US$ 6.4 Billion in 2023. Actinic keratosis refers to a skin condition caused by extended exposure to ultraviolet (UV) radiation from the sun. The instance is exaggerated by a poor immune system, old age, predisposing disease, and side effects of certain drugs. Actinic keratosis leads to rough and scaly patches, redness, raised bumps, bleeding, and tenderness on the face, nose, ears, cheeks, lips, forehead, and scalp. Its treatment includes surgical procedures, topical medications, cryotherapy, curettage, photodynamic therapy (PDT), chemical peel, and laser resurfacing. Actinic keratosis treatment promotes skin cells’ growth, minimizes damage to healthy tissue, reduces scarring, and eases various symptoms, such as itching, pain, bleeding, and tenderness.

Global Actinic Keratosis Treatment Market Trends:

The rising prevalence of actinic keratosis due to global warming, depletion of the ozone layer, and excessive sun exposure are among the key factors driving the market growth. Various treatment options are adopted depending on the severity of the condition to remove and prevent its re-occurrence, treat symptoms, and promote healthy skin growth. Additionally, increasing demand for minimally invasive (MI) treatments that are cost-effective and offer faster recovery is acting as another growth-inducing factor. Furthermore, the widespread treatment adoption due to the rising concerns regarding the cancerous nature of actinic keratosis that may develop into squamous cell carcinoma, basal cell carcinoma, melanoma, and Merkel cell carcinoma, if left untreated, is providing an impetus to the market growth. Apart from this, the integration of a convolutional neural network (CNN) to develop an intelligent diagnostic system capable of differentiating actinic keratosis symptoms from other skin conditions to enhance the accuracy of clinical diagnosis, aid in early detection, facilitate self-monitoring, and assist in accurate treatment is positively influencing the market growth. Moreover, the extensive research and development (R&D) activities to develop novel therapies with improved efficacy and the introduction of cream and gel to treat actinic keratosis are propelling the market growth. Other factors, including rising consumer awareness regarding early and effective treatments for actinic keratosis, implementation of various government initiatives to develop more affordable healthcare facilities, and widespread availability of generic drugs, are anticipated to drive the market growth. On account of the aforementioned factors, the market value is expected to reach US$ 9.7 Billion by 2032, exhibiting a CAGR of 4.5% during 2024-2032.

Market Summary:

On the basis of the type, the market has been bifurcated into prescription and OTC.
Based on the drug type, the market has been divided into fluorouracil, imiquimod, diclofenac, and others.
On the basis of the distribution channel, the market has been classified into hospital pharmacies, drug stores and retail pharmacies, and online stores.
On a regional basis, the market has been categorized into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
The competitive landscape of the industry has also been examined, with some of the key players being 3M Company, Almirall SA, Bausch Health Companies Inc., Biofrontera Inc., BioLineRx Ltd., Cipher Pharmaceuticals Inc, Galderma SA, Hill Dermaceuticals Inc., LEO Pharma A/S and Sun Pharmaceutical Industries Ltd.

Report Scope:

Report Features	Details
Base Year of the Analysis	2023
Historical Period	2018-2023
Forecast Period	2024-2032
Units	US$ Billion
Segment Coverage	Type, Drug Type, Distribution Channel, Region
Region Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered	United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered	3M Company, Almirall SA, Bausch Health Companies Inc., Biofrontera Inc., BioLineRx Ltd., Cipher Pharmaceuticals Inc, Galderma SA, Hill Dermaceuticals Inc., LEO Pharma A/S and Sun Pharmaceutical Industries Ltd.
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St, Ste
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Global Actinic Keratosis Treatment Market to Reach US$ 9.7 Billion by 2032, Propelled by Rising Prevalence of Actinic Keratosis

Purchase options

Single User License ~~$3899~~ $2999
Five User License ~~$4899~~ $3999
Corporate User License ~~$5899~~ $4999

Inquire Before Buying

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.